News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
REGULATION
Law & Regulation
MAH
Pharmacovigilance
Marketing Approval
Priority Review
Health Insurance
Innovative Drug
Generic Drug
Rare Disease
Drug Registration
New Drug
China Encourages Innovative Drug R&D in Revised Draft of Regulations for Implementing the Drug Administration Law
Find out the highlights in revised draft of the Regulations for Implementation of the Drug Administration Law: pharmaceutical innovation, acceptance of foreign clinical data, support the development of pediatric and rare disease drugs...
May 13, 2022
INDUSTRY
Marketing Approval
Priority Review
Innovative Drug
Generic Drug
Biological Product
Cancer
Cardiovascular Disease
Rare Disease
Drug Registration
New Drug
Monthly Report: New Drug Approvals in China | March 2022
In March 2022, China NMPA approved 23 new drugs, including 15 chemical drugs and 8 biological products.
Apr 07, 2022
INDUSTRY
Multinational Pharma Companies Record Sales Growth in 2021
Johnson & Johnson ranks the first with global sales of 93.77 billion USD.
Pfizer has the most rapid growth in global sales, zooming up by 95% to 81.3 billion USD.
AstraZeneca is the largest foreign pharma company regarding its 5.99 billion USD sales in China.
MSD records the most vigorous sales growth in China of 60%, bringing the sales to 4.26 billion USD.
Mar 18, 2022
POLICY
Law & Regulation
Marketing Approval
Volume-based Procurement
Health Insurance
Innovative Drug
Cancer
Cardiovascular Disease
Rare Disease
Drug Registration
New Drug
China's 2022 Two Sessions: Goals and Proposals for Pharma & Healthcare Industry
China's Government Work Report says one off the major tasks for 2022 is to improve medical and health services.
Mar 15, 2022
INDUSTRY
Marketing Approval
Priority Review
Innovative Drug
Generic Drug
Biological Product
Cancer
Drug Registration
New Drug
COVID-19
Monthly Report: New Drug Approvals in China | February 2022
In February 2022, China NMPA approved 16 new drugs, including 12 chemical drugs and 4 biological products. Among the newly approved drugs, Pfizer’s Paxlovid is the first foreign drug against COVID-19 to receive marketing authorization in China.
Mar 11, 2022
REGULATION
Law & Regulation
Marketing Approval
Clinical Trial
Priority Review
Innovative Drug
API
Rare Disease
New Drug
The 15th Rare Disease Day: China's Policy & Market Overview
China tries to make rare disease drugs available to more patients via measures like expediting the marketing approval of the drugs and reimbursing part of the medical expenses. Meanwhile, the rare disease treatment market is expanding rapidly.
Mar 04, 2022
REGULATION
Most Popular
- Decoding China's Good Pharmacovigilance Practices (GVP)
- Monthly Report: New Drug Approvals in China | February 2024
- 2023 China CDE Drug Evaluation Report
- Monthly Recap: China Pharmaceutical Regulatory Updates | February 2024
- [Updated] China Expedites Process for Transferring Overseas Drug Manufacturing Sites to China